Transition, Actinide, Or Lanthanide Metal Containing Patents (Class 424/9.36)
-
Patent number: 7279150Abstract: Compounds useful for associating with nanoparticle or microparticle emulsions to obtain magnetic resonance images permit control of the relaxivity of the signal and readily associate with the particulate components.Type: GrantFiled: January 26, 2004Date of Patent: October 9, 2007Assignees: Barnes-Jewish Hospital, The Dow Chemical CorporationInventors: Gregory M. Lanza, Samuel A. Wickline, Phillip S. Athey, Gyongyi Gulyas, Garry E. Kiefer
-
Patent number: 7244413Abstract: Provided are a functionalized, encapsulated fluorescent nanocrystal comprising a liposome having encapsulated therein one or more fluorescent nanocrystals; use of the functionalized, encapsulated fluorescent nanocrystals in detection systems; and a method of producing functionalized, encapsulated fluorescent nanocrystals. A method of using the functionalized encapsulated fluorescent nanocrystals having affinity molecule bound thereto comprises contacting the functionalized encapsulated fluorescent nanocrystals with a sample so that complexes are formed between the functionalized encapsulated fluorescent nanocrystals and substrate for which the affinity molecule has binding specificity, if the substrate is present; exposing the complexes in the detection system to an excitation light source, and detecting a fluorescence peak emitted from the complexes, if present.Type: GrantFiled: December 12, 2005Date of Patent: July 17, 2007Assignee: Invitrogen CorporationInventor: Emilio Barbera-Guillem
-
Patent number: 7238341Abstract: Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents.Type: GrantFiled: February 25, 2004Date of Patent: July 3, 2007Assignee: Epix Pharmaceuticals, Inc.Inventors: Zhaoda Zhang, John C. Amedio, Peter D. Caravan, Stephane Dumas, Andrew Kolodziej, Thomas J. McMurry
-
Patent number: 7229606Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Type: GrantFiled: January 12, 2004Date of Patent: June 12, 2007Assignee: Epix Pharmaceuticals, Inc.Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
-
Patent number: 7226578Abstract: The invention relates to new, monomeric, perfluoroalkyl-substituted metal complexes, processes for their production, and their use in diagnosis and therapy. The compounds according to the invention are suitable especially as in vivo contrast media in nuclear spin tomography (MRT). They can preferably be used as blood-pool agents and as lymphographic agents.Type: GrantFiled: October 5, 2004Date of Patent: June 5, 2007Assignee: Shering aGInventors: Johannes Platzek, Ulrich Niedballa, Bernd Radüchel, Wolfgang Schlecker, Hanns-Joachim Weinmann, Thomas Frenzel, Bernd Misselwitz, Wolfgang Ebert
-
Patent number: 7211241Abstract: Described are new cascade polymer complexes, compositions containing them and use of the complexes in diagnosis and therapy, particularly for magnetic resonance imaging and computer tomography imaging.Type: GrantFiled: October 17, 2003Date of Patent: May 1, 2007Assignee: Schering AktiengesellschaftInventors: Heribert Schmitt-Willich, Johannes Platzek, Bernd Radüchel, Andreas Mühler, Thomas Frenzel
-
Patent number: 7208139Abstract: Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21–29, 39, 42, 44 or 57–83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.Type: GrantFiled: September 30, 2004Date of Patent: April 24, 2007Assignee: Schering AGInventors: Johannes Platzek, Heribert Schmitt-Willich, Heinz Gries, Gabriele Schuhmann-Giampieri, Hubert Vogler, Hanns-Joachim Weinmann, Hans Bauer
-
Patent number: 7198776Abstract: The invention relates to metal complex compounds, contrast agents for MRI and in vivo NMR markers for NMR spectroscopy comprising said metal complex compounds and methods for in vivo determination of physiological parameters, e.g. enzyme activity or pH using said metal complex compounds.Type: GrantFiled: November 28, 2002Date of Patent: April 3, 2007Assignee: GE Healthcare ASInventors: Jo Klaveness, Pal Rongved
-
Patent number: 7186400Abstract: Compounds of general formula (I): in which: R1 is hydrogen, C1–C20 alkyl, C3–C10 cycloalkyl, C4–C20 cycloalkylalkyl, aryl, arylalkyl, or two R1, taken together, form a straight or cyclic C2–C10 alkylene group or an ortho disubstituted arylene; R2 is hydrogen, C1–C20 alkyl, C3–C10 cycloalkyl, C4–C20 cycloalkylalkyl, aryl or aryl alkyl optionally substituted with functional groups which allow conjugation with a suitable molecule able to interact with physiological systems; R3, R4 and R5 are hydrogen, C1–C20 alkyl, C3–C10 cycloalkyl, C4–C20 cycloalkylalkyl, aryl, arylalkyl; and their chelates with bi-trivalent ions of the metal elements having atomic number ranging between 20 and 31, 39, 42, 43, 44, 49, and between 57 and 83, and radioisotopes chosen among 203Pb 67Ga 68Ga 72As 111In 113In 90Y 97Ru 62Cu 64Cu 52Fe 52mMn 140La 175Yb 153Sm 166Ho 149Pm 177Lu 142Pr 159Gd 212Bi 47Sc 149Pm 67Cu, 111Ag, 199Au, 161Tb and 51Cr as well as the salts thereof with physiologically compatible bases or acidsType: GrantFiled: July 10, 2002Date of Patent: March 6, 2007Assignee: Bracco Imaging S.p.A.Inventors: Giovanni Battista Giovenzana, Giovanni Palmisano, Massimo Sisti, Camilla Cavallotti, Silvio Aime, Luisella Calabi
-
Patent number: 7179450Abstract: In certain embodiments, methods of the present invention obtain dynamic data sets of an NMR spectroscopy signal of polarized 129Xe in a selected structure, environment, or system. The signal data can be used to evaluate: (a) the physiology of a membrane or tissue; (b) the operational condition or function of a body system or portion thereof (when at rest or under stimulation); and/or (c) the efficacy of a therapeutic treatment used to treat a diagnosed disorder, disease, or condition. Thus, the present invention provides methods for screening and/or diagnosing a respiratory, cardiopulmonary disorder or disease such as chronic heart failure, and/or methods for monitoring the efficacy of therapeutics administered to subject to treat the disorder or disease.Type: GrantFiled: January 31, 2003Date of Patent: February 20, 2007Assignee: Medi-Physics, Inc.Inventors: Bastiaan Driehuys, Margaret Hall, Claudio Marelli, Sven Mansson, Jan Wolber
-
Patent number: 7175829Abstract: The present invention relates to a contrast-enhanced diagnostic imaging method for monitoring the efficacy of interventional therapies. The contrast agents useful in this method comprise an image-enhancing moiety (IEM) and a state-dependent tissue binding moiety (SDTBM). These contrast agents exhibit state-dependent binding to one or more components of a targeted tissue or tissue component and provide a detectable change in the signal characteristics of the agent once bound to the targeted tissue. As a result, these agents exhibit a binding affinity for, and thus image contrast of, the targeted tissue which changes as the tissue-state changes during therapy.Type: GrantFiled: October 8, 2004Date of Patent: February 13, 2007Assignee: Epix Pharmaceuticals, Inc.Inventors: Randall B. Lauffer, Stephen O. Dunham
-
Patent number: 7138105Abstract: In part, the present invention is directed to compositions comprising a carrier with a metal binding domain, a metal ion, and an active agent.Type: GrantFiled: February 27, 2003Date of Patent: November 21, 2006Assignee: PharmaINInventor: Elijah M. Bolotin
-
Patent number: 7132513Abstract: The invention concerns a ligand comprising wherein n is an integer from 1 to 5, X represents —NO2, —NH2, —NCS, —NHCOCH2-Z. NHCO—W—COCNHS, —NH-Q, —NHCS-Q, —NHCOCH2-Q, or —NHCO(CH2)m ?-Q where Q is an hapten chosen from the group consisting of steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof or any activated linker ready for coupling reaction, Y is CO2H or PO3H2 W is —(CH2)m— m is an integer from 1 to 10.Type: GrantFiled: March 9, 2001Date of Patent: November 7, 2006Assignees: European Community, INSERM Insitut National de la Santé et de la Recherche MédicaleInventors: Ali Ouadi, Jean-François Gestin, Christos Apostolidis
-
Patent number: 7128895Abstract: The use of contrast agents of molecular weight lower than 5000 Dalton and including at least one residue of a biliary acid for the preparation of diagnostic contrast compositions for the microvascular permeability assessment is disclosed.Type: GrantFiled: April 17, 2001Date of Patent: October 31, 2006Assignees: Bracco Imaging S.p.A., The Regents of the University of CaliforniaInventors: Friedrich Cavagna, Timothy P. L. Roberts
-
Patent number: 7110806Abstract: The present invention is a technique and apparatus for acquiring anatomic information used in diagnosing and characterizing abdominal aortic aneurismal disease and the like. This technique provides anatomic information, in the form of images, using a combination of a plurality of magnetic resonance angiography sequences, including a spin-echo and four contrast enhanced (e.g., gadolinium) magnetic resonance angiography sequences. The anatomic images may be used in, for example, pre-operative, operative and post-operative evaluation of aortic pathology, including aneurysms, atherosclerosis, and occlusive disease of branch vessels such as the renal arteries. The gadolinium-enhanced magnetic resonance angiography provides sufficient anatomic detail to detect aneurysms and all relevant major branch vessel abnormalities seen at angiography operation.Type: GrantFiled: August 26, 2003Date of Patent: September 19, 2006Inventor: Martin R. Prince
-
Patent number: 7074387Abstract: Compounds of formula I wherein Z1, Z2, X, R2 and R3 are as defined herein, are suitable as NMR shift reagents.Type: GrantFiled: March 25, 2003Date of Patent: July 11, 2006Assignee: Schering AGInventors: Heinz Gries, Erich Klieger, Bernd Raduechel, Heribert Schmitt-Willich, Hanns-Joachim Weinmann, Hubert Vogler, Gabriele Schuhmann-Giampieri, Juergen Conrad
-
Patent number: 7060252Abstract: Provided are a functionalized, encapsulated fluorescent nanocrystal comprising a liposome having encapsulated therein one or more fluorescent nanocrystals; use of the functionalized, encapsulated fluorescent nanocrystals in detection systems; and a method of producing functionalized, encapsulated fluorescent nanocrystals. A method of using the functionalized encapsulated fluorescent nanocrystals having affinity molecule bound thereto comprises contacting the functionalized encapsulated fluorescent nanocrystals with a sample so that complexes are formed between the functionalized encapsulated fluorescent nanocrystals and substrate for which the affinity molecule has binding specificity, if the substrate is present; exposing the complexes in the detection system to an excitation light source, and detecting a fluorescence peak emitted from the complexes, if present.Type: GrantFiled: June 14, 2004Date of Patent: June 13, 2006Assignee: BioCrystal, Ltd.Inventor: Emilio Barbera-Guillem
-
Patent number: 7045606Abstract: The invention concerns a ligand comprising (I) wherein n is an integer from 1 to 5 Y is CO2H or PO3H2T represents —X or -phenyl-X, wherein X represents NO2, NH2, NCS, NHCOCH2-Z, NHCO—W—COCNHS, —NH-Q, —NHCS-Q, —NHCOCH2-Q, or NHCO(CH2)m-Q where Q is a hapten chosen from the group consisting of steroids, enzymes, proteins, monoclonal antibodies, chimeric antibodies, or fragments thereof or any activated linker ready for coupling reaction, W is —(CH2)m- m is an integer from 1 to 10 Z is chloride, bromide or iodineType: GrantFiled: September 13, 2002Date of Patent: May 16, 2006Assignee: European CommunityInventors: Ali Ouadi, Jean-Francois Gestin, Christos Apostolidis
-
Patent number: 7029655Abstract: The invention relates to a novel class of magnetic resonance imaging agents that can cross the blood brain barrier and provide accurate magnetic resonance imaging of the brain, especially magnetic resonance images of amyloid deposits associated with Alzheimer's disease.Type: GrantFiled: October 4, 2001Date of Patent: April 18, 2006Assignee: California Institute of TechnologyInventors: Matthew J. Allen, Scott Fraser, Russell E. Jacobs, Thomas J. Meade
-
Patent number: 7020578Abstract: A method of evaluating novel stroke treatments includes generating a risk map indicative of the probability of tissue infarction on voxel-by-voxel basis and selecting a probability range for evaluating the therapeutic effect of the novel treatment. In one particular embodiment, tissue having a fifty percent probability of tissue infarction is selected. A novel treatment that has a reduced level of overall actual infarction as compared to the predicted value is indicative of therapeutic effect.Type: GrantFiled: February 2, 2001Date of Patent: March 28, 2006Assignee: The General Hospital CorporationInventors: Gregory A. Sorensen, Ona Wu
-
Patent number: 7011815Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Type: GrantFiled: January 30, 2003Date of Patent: March 14, 2006Assignee: Epix Pharmaceuticals, Inc.Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
-
Patent number: 6994841Abstract: The invention shows a method for obtaining temporally spaced images of tissues, including blood vessels, to reveal blood flow abnormalities within those tissues and vessels.Type: GrantFiled: November 9, 1998Date of Patent: February 7, 2006Assignee: Kucharczyk and Moseley PartnersInventors: Scott M Rocklage, John Kucharczyk, Michael E Moseley
-
Patent number: 6982324Abstract: Novel degradable macromolecular magnetic resonance imaging contrast agents for use in various diagnostic procedures, and methods for synthesizing, using and degrading these agents, are disclosed. The macromolecule contrast agents disclosed in various aspects of this invention are degradable gadolinium compounds which show prolonged plasma retention, and enhanced permeability and retention in solid tumors, but are still capable of being rapidly cleared from the body.Type: GrantFiled: November 5, 2002Date of Patent: January 3, 2006Assignee: University of Utah Research FoundationInventors: Zheng-Rong Lu, Jindrich Kopecek, Dennis L. Parker
-
Patent number: 6926883Abstract: The invention relates to novel aminocarboxylate ligands that are suitable for complexing with a radionuclide, and are useful as imaging agents for diagnostic purposes. In accordance with the present invention, a method of preparing a compound of formula (I): fac-[M(CO)3(OH2)3]+, wherein M is Mn, 99mTc, 186Re or 188Re, involves reacting a metal in permetallate form with carbon monoxide and a reducing agent, wherein a mixture of a basic borate buffer and a reducing agent soluble in water but not substantially decomposed by water is solved in a water containing solvent system containing a solution of the metal in permanganate, pertechnetate or perrhenate form in the presence of carbon monoxide. The compound of formula (I) can be reacted with a ligand Lx to form a compound of formula (II): fac-[M(CO)3(X)2L1]n, wherein M is as defined above Lx is a multidentate ligand, and n is a charge of the ligand Lx increased with one + charge.Type: GrantFiled: June 28, 2000Date of Patent: August 9, 2005Assignee: Mallinckrodt IncInventors: Mary M. Dyszlewski, Roger Alberto, Joseph E. Bugaj
-
Patent number: 6916461Abstract: The invention relates to new, monomeric, perfluoroalkyl-substituted metal complexes, processes for their production, and their use in diagnosis and therapy. The compounds according to the invention are suitable especially as in vivo contrast media in nuclear spin tomography (MRT). They can preferably be used as blood-pool agents and as lymphographic agents.Type: GrantFiled: July 18, 2002Date of Patent: July 12, 2005Assignee: Schering AGInventors: Johannes Platzek, Ulrich Niedballa, Bernd Radüchel, Wolfgang Schlecker, Hanns-Joachim Weinmann, Thomas Frenzel, Bernd Misselwitz, Wolfgang Ebert
-
Patent number: 6911457Abstract: The present invention relates to novel imaging probes and methods for using the probes in diagnostic imaging processes and other imaging processes to determine physiological functions.Type: GrantFiled: April 11, 2003Date of Patent: June 28, 2005Assignee: Carbomer, Inc.Inventor: Manssur Yalpani
-
Patent number: 6899864Abstract: The present invention provides a kit and a method for targeting of a diagnostic or therapeutic agent to a target site in a mammal having a pathological condition. The kit comprises, in separate containers, (a) a first conjugate comprising a targeting moiety and a Morpholino oligomer, wherein the targeting moiety selectively binds to a primary, target-specific binding site of the target site or to a substance produced by or associated with the target site; (b) optionally, a clearing agent; and (c) a second conjugate comprising a complementary Morpholino oligomer and a diagnostic agent or therapeutic agent. The method comprises administering (a), optionally (b), and (c) to a mammal.Type: GrantFiled: April 1, 2002Date of Patent: May 31, 2005Assignee: Immunomedics, Inc.Inventors: Donald J. Hnatowich, Mary Rusckowski, Guozheng Liu
-
Patent number: 6896874Abstract: The present invention provides a coating that emits magnetic resonance signals and a method for coating medical devices therewith. The coating includes a paramagnetic metal ion-containing polymer complex that facilitates diagnostic and therapeutic techniques by readily visualizing medical devices coated with the complex. The present invention also provides methods by which pre-existing polymers and medical devices may be made MR-imageable. The invention also provides methods of improving MR-imageability of polymers and medical devices by encapsulating the polymers and medical devices with hydrogels.Type: GrantFiled: May 9, 2002Date of Patent: May 24, 2005Assignee: Wisconsin Alumni Research FoundationInventors: Junwei Li, Orhan Unal, Xiqun Jiang, Charles Milton Strother, Hyuk Yu
-
Patent number: 6875419Abstract: The present invention is directed, in general, to contrast agents (CA), and methods and systems of using such agents for producing image contrast based on a magnetization transfer (MT) mechanism. The CA comprises a tetraazacyclododecane ligand having pendent arms R, R?, R? and R?? that are amides having a general formula: —CR1H—CO—NH—CH2—R2. R1 includes organic substituents and R2 is not hydrogen. A paramagnetic metal ion (M) is coordinated to the ligand. The method, comprises subjecting a CA, in a sample, to a radio frequency pulse. The CA has pendent arms R, R?, R? and R?? comprising organic substituents and the ligand further includes a M and a water molecule. A signal is obtained by applying a radio frequency pulse at a resonance frequency of the water molecule. The magnetic resonance system, comprises a magnetic resonance apparatus and the CA, the agent containing a ligand having the above described general formula.Type: GrantFiled: November 20, 2001Date of Patent: April 5, 2005Assignee: Board of Regents The University of Texas SystemInventors: A. Dean Sherry, Shanrong Zhang, Kuangcong Wu
-
Patent number: 6861045Abstract: The present invention relates to a contrast-enhanced diagnostic imaging method for monitoring the efficacy of interventional therapies. The contrast agents useful in this method comprise an image-enhancing moiety (IEM) and a state-dependent tissue binding moiety (SDTBM). These contrast agents exhibit state-dependent binding to one or more components of a targeted tissue or tissue component and provide a detectable change in the signal characteristics of the agent once bound to the targeted tissue. As a result, these agents exhibit a binding affinity for, and thus image contrast of, the targeted tissue which changes as the tissue-state changes during therapy.Type: GrantFiled: September 8, 2000Date of Patent: March 1, 2005Inventors: Randall B. Lauffer, Stephen O. Dunham
-
Patent number: 6855551Abstract: The present invention provides a composition comprising fluorescent semiconductor nanocrystals associated to a compound, wherein the nanocrystals have a characteristic spectral emission, wherein said spectral emission is tunable to a desired wavelength by controlling the size of the nanocrystal, and wherein said emission provides information about a biological state or event.Type: GrantFiled: April 12, 2001Date of Patent: February 15, 2005Assignee: Massachusetts Institute of TechnologyInventors: Moungi G. Bawendi, Vikram C. Sundar, Frederic V. Mikulec
-
Patent number: 6855309Abstract: Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21-29, 39, 42, 44 or 57-83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.Type: GrantFiled: December 11, 2002Date of Patent: February 15, 2005Assignee: Schering, AGInventors: Johannes Platzek, Heribert Schmitt-Willich, Heinz Gries, Gabriele Schuhmann-Giampieri, Hubert Vogler, Hanns-Joachim Weinmann, Hans Bauer
-
Patent number: 6852842Abstract: Small dendrimer-based MRI contrast agents are disclosed to accumulate in renal tubules. The accumulation enables visualization of renal structure and function, permitting assessment of structural and functional damage to the kidneys. In a disclosed embodiment, six, small dendrimer-based MRI contrast agents were synthesized, and their pharmacokinetics, whole body retention, and renal MRI images were evaluated in mice. Surprisingly, despite having unequal renal clearance properties, all of the dendrimer agents clearly visualized the renal anatomy and proximal straight tubules of the mice better than Gd-[DTPA]-dimeglumine. Dendrimer conjugate contrast agents prepared from PAMAM-G2D, DAB-G3D, and DAB-G2D dendrimers were excreted rapidly and may be acceptable for use in clinical applications.Type: GrantFiled: August 26, 2002Date of Patent: February 8, 2005Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Martin W. Brechbiel, Robert A. Star, Hisataka Kobayashi
-
Publication number: 20040258619Abstract: The present invention relates to improved chelator conjugates with biological targeting molecules, suitable for forming metal complexes with radiometals. The radiometal complexes, especially with the radiometal99mTc, are useful as radiopharmaceuticals.Type: ApplicationFiled: June 21, 2004Publication date: December 23, 2004Inventors: Colin Mill Archer, Harry John Wadsworth, Torgrim Engell
-
Patent number: 6818203Abstract: The invention relates to the use of perfluoroalkyl-containing metal complexes that have a critical micelle formation concentration <10−3 mol/l, a hydrodynamic micelle diameter (2 Rh)>1 nm and a proton relaxivity in plasma (R1)>10 l/mmol·s) as contrast media in MR imaging for visualization of plaque, lymph nodes, infarcted and necrotic tissue and for independent visualization of necrotic tissue and tumor tissue.Type: GrantFiled: August 10, 2001Date of Patent: November 16, 2004Assignee: Schering AktiengesellschaftInventors: Johannes Platzek, Peter Mareski, Ulrich Niedballa, Bernd Raduechel, Hanns-Joachim Weinmann, Bernd Misselwitz
-
Patent number: 6808699Abstract: MR spectroscopy and imaging methods for imaging pulmonary and cardiac vasculature and the cardiac region and evaluating blood flow or circulatory deficits use dissolved phase polarized 129Xe gas and large flip angle excitation pulses. Pulmonary and cardiac vasculature MRI images are obtained by delivering gas to a patient via inhalation such as with a breath-hold delivery-procedure, exciting the dissolved phase gas with a large flip angle pulse, and generating a corresponding image. Preferably, the image is obtained using multi-echo imaging techniques. Blood flow is quantified using low field MR spectroscopy and an RF excitation pulse with a frequency which corresponds to the resonance of the dissolved phase 129Xe.Type: GrantFiled: December 9, 2002Date of Patent: October 26, 2004Assignee: Medi-Physics, Inc.Inventors: Bastiaan Driehuys, Kenton Christopher Hasson, Paul Lev Bogorad
-
Publication number: 20040208825Abstract: This invention comprises nanoparticles for use with biosensors. The nanoparticles have core/shell architecture. The nanoparticles can be detected by two means, magnetic and optical by virtue of the nanoparticles magnetic core and fluorescent semiconductor shell. Methods of making the nanoparticles and their composition are described.Type: ApplicationFiled: April 15, 2003Publication date: October 21, 2004Inventors: Everett E. Carpenter, Vincent Carpenter
-
Publication number: 20040208827Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.Type: ApplicationFiled: January 12, 2004Publication date: October 21, 2004Applicant: Epix Medical, Inc., a Delaware corporationInventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
-
Publication number: 20040175329Abstract: There is disclosed a method for visualizing a body lumen. The method of the invention uses contrast material that preferably adheres to the interior wall of a target body lumen for a period of time sufficient to permit real-time visualization of the lumen and to enable the performance of image-guided diagnostic and therapeutic procedures. Lumens from the cardio-vascular, pulmonary, digestive, reproductive, excretory and central nervous systems may conveniently be visualized. Radiography, nuclear medicine, ultrasound and MRI visualizing systems may be used. Contrast materials for use in the invention are non-toxic, especially non-toxic to the kidney, do not produce allergic reactions, do not stimulate atherogenesis, and preferably comprise iodine or a metal.Type: ApplicationFiled: March 7, 2003Publication date: September 9, 2004Inventor: John Steele Fisher
-
Patent number: 6776977Abstract: Tripodal polyaminophosphonate chelants are disclosed, as well as chelates of the chelants with metal ions to form radiopharmaceutical and radioactive, MRI and X-ray or CT imaging compounds and compositions. Therapeutic and imaging methods of use are also disclosed.Type: GrantFiled: December 27, 2001Date of Patent: August 17, 2004Assignee: Bristol-Myers Squibb Pharma CompanyInventor: Shuang Liu
-
Publication number: 20040156785Abstract: The present invention relates to improved diagnostic agents for Magnetic Resonance Imaging and optical imaging. In particular, this invention relates to MRI and optical imaging agents that allow for the sensitive detection of a specific bioactivity within a tissue. These agents are prodrug contrast agents which are bioactivated in vivo in the presence of the specific bioactivity. This invention also relates to pharmaceutical compositions comprising these agents and to methods of using the agents and compositions comprising the agents.Type: ApplicationFiled: January 16, 2004Publication date: August 12, 2004Applicant: Epix Medical , Inc., a Delaware corporationInventors: Randall B. Lauffer, Thomas J. McMurry, Stephen O. Dunham, Daniel M. Scott, David J. Parmelee, Stephane Dumas
-
Patent number: 6770020Abstract: Described is a method of using gadolinium-containing compounds as agents for neutron capture therapy to treat neoplastic cell growth. The subject is exposed to a gadolinium-containing compound for a time sufficient to allow the compound to accumulate in neoplastic cells. The subject is then exposed to a thermal and/or epithermal neutron flux, thereby initiating a neutron capture reaction in the gadolinium atoms that results in specific death of neoplastic cells.Type: GrantFiled: April 30, 2002Date of Patent: August 3, 2004Assignee: Wisconsin Alumni Research FoundationInventors: Gelsomina De Stasio, Benjamin Gilbert, Bradley H. Frazer, Roberto Pallini, Luigi Maria Larocca, Delio Mercanti, Patrizia Casalbore
-
Patent number: 6770261Abstract: The invention relates to novel magnetic resonance imaging contrast agents and methods of detecting physiological signals or substances.Type: GrantFiled: May 24, 2001Date of Patent: August 3, 2004Assignee: Research Corporation TechnologiesInventors: Thomas J. Meade, Scott Fraser
-
Patent number: 6761877Abstract: Provided are a functionalized, encapsulated fluorescent nanocrystal comprising a liposome having encapsulated therein one or more fluorescent nanocrystals; use of the functionalized, encapsulated fluorescent nanocrystals in detection systems; and a method of producing functionalized, encapsulated fluorescent nanocrystals. A method of using the functionalized encapsulated fluorescent nanocrystals having affinity molecule bound thereto comprises contacting the functionalized encapsulated fluorescent nanocrystals with a sample so that complexes are formed between the functionalized encapsulated fluorescent nanocrystals and substrate for which the affinity molecule has binding specificity, if the substrate is present; exposing the complexes in the detection system to an excitation light source, and detecting a fluorescence peak emitted from the complexes, if present.Type: GrantFiled: February 12, 2001Date of Patent: July 13, 2004Assignee: BioCrystal, Ltd.Inventor: Emilio Barbera-Guillem
-
Publication number: 20040131546Abstract: The invention relates to the use of perfluoroalkyl-containing metal complexes that have a critical micelle formation concentration <10−3 mol/l, a hydrodynamic micelle diameter (2 Rh)>1 nm and a proton relaxivity in plasma (R)>10 l/mmol s as contrast media in MR imaging for visualization of intravascular thrombi.Type: ApplicationFiled: July 10, 2003Publication date: July 8, 2004Applicant: Schering AGInventors: Bernd Misselwitz, Johannes Platzek, Yoko Kawata, Hanns-Joachim Weinmann, Takashi Yokawa, Ulrich Niedballa
-
Patent number: 6709646Abstract: The present invention relates to improved diagnostic agents for Magnetic Resonance Imaging and optical imaging. In particular, this invention relates to MRI and optical imaging agents that allow for the sensitive detection of a specific bloactivity within a tissue. These agents are prodrug contrast agents which are bioactivated in vivo in the presence of the specific bioactivity. This invention also relates to pharmaceutical compositions comprising these agents and to methods of using the agents and compositions comprising the agents.Type: GrantFiled: September 14, 2001Date of Patent: March 23, 2004Assignee: Epix Medical, Inc.Inventors: Randall B. Lauffer, Thomas J. McMurry, Stephen O. Dunham, Daniel M. Scott, David J. Parmelee, Stéphane Dumas
-
Publication number: 20040042959Abstract: An annexin, annexin analogue or phosphatidylserine binding compound (PSC) labeled with an MR, CT, or optical contrast agent. The conjugate is administered into a subject and specifically binds to the surface of apoptotic and necrotic cells. The subject is imaged using conventional MRI, CT and optical imaging techniques and dead and dying tissue is identified. The identification and development of analogues specific for phosphatidylserine for purposes of non-invasive imaging of dead or dying cells.Type: ApplicationFiled: August 28, 2002Publication date: March 4, 2004Inventors: Michael Montalto, Bruce Johnson, Mohan Amaratunga
-
Publication number: 20040042963Abstract: This invention describes a novel strategy to produce phosphine-functionalized biomolecules (e.g. peptides or proteins) for potential use in the design and development of site-specific radiopharmaceuticals for diagnosis or therapy of specific cancers. Hydrophilic alkyl phosphines, in general, tend to be oxidatively unstable. Therefore, incorporation of such phosphine functionalities on peptide (and other biomolecule) backbones, without oxidizing the PIII centers, is difficult. In this context this discovery reports on a new technology by which phosphines, in the form of bifunctional chelating agents, can be directly incorporated on biomolecular backbones using manual synthetic or solid phase peptide synthesis methodologies. The superior ligating abilities of phosphine ligands, with various diagnostically (e.g. TC-99m) or therapeutically (e.g.Type: ApplicationFiled: August 31, 1999Publication date: March 4, 2004Inventors: KATTESH V. KATTI, HARIPRASAD GALI, WYNN A. VOLKERT
-
Patent number: 6699723Abstract: A semiconductor nanocrystal compound is described capable of linking to an affinity molecule. The compound comprises (1) a semiconductor nanocrystal capable of emitting electromagnetic radiation and/or absorbing energy, and/or scattering or diffracting electromagnetic radiation—when excited by an electromagnetic radiation source or a particle beam; and (2) at least one linking agent, having a first portion linked to the semiconductor nanocrystal and a second portion capable of linking to an affinity molecule. The compound is linked to an affinity molecule to form a semiconductor nanocrystal probe capable of bonding with a detectable substance. Subsequent exposure to excitation energy will excite the semiconductor nanocrystal in the probe, causing the emission of electromagnetic radiation.Type: GrantFiled: May 24, 2001Date of Patent: March 2, 2004Assignee: The Regents of the University of CaliforniaInventors: Shimon Weiss, Marcel Bruchez, Jr., Paul Alivisatos
-
Patent number: 6686458Abstract: The present invention features biarsenical molecules. Target sequences that specifically react with the biarsenical molecules are also included. The present invention also features kits that include biarsenical molecules and target sequences. Tetraarsenical molecules are also featured in the invention.Type: GrantFiled: April 19, 2002Date of Patent: February 3, 2004Assignee: The Regents of the University of CaliforniaInventors: Roger Y. Tsien, B. Albert Griffin